Aim: The co-existence of type 2 diabetes (T2D) with nonalcoholic fatty liver disease (NAFLD) significantly increases the prevalence of advanced fibrosis and end-stage liver disease, as well as cardiovascular disease risk and mortality. Fibrosis 4 (FIB-4) index has been described as a non-invasive marker to detect liver fibrosis, based on several laboratory texts (AST/ALT/Platelets) . This study aimed to explore the relationship between FIB-4 index and macroalbuminuria in patients with T2D and NAFLD.
Methods: This cross-sectional utilized data in Tibetan patients with T2D and NAFLD from 2020-2021. Patients were divided into two groups based on FIB-4 index (group 1: FIB-4<1.45; group 2: FIB-4≥1.45) . Reduced eGFR was defined as eGFR <60 ml/min per 1.73 m2 and macroalbuminuria was defined as urinary albumin/creatine ≥ 300 mg/g.
Results: A total of 362 patients were recruited. Clinical characteristics of subjects were showed in Table 1. In Multiple logistic regression analysis, compared to patients with FIB-4 <1.45, those with FIB-4 ≥ 1.45 were at a 2.26-fold (95% CI:1.08-4.73) for macroalbuminuria, after adjusted for age, gender, duration of T2D, BMI, LDL-C, HbA1c and hypertension. However, FIB-4 index was not associated with reduced eGFR (OR: 2.34, 95% CI: 0.89-6.18) .
Conclusions: Our finding showed that an increase in FIB-4 index was independently associated with macroalbuminuria in T2D patients with NAFLD.